YM BioSciences (YM-T) Stock Predictions - Stockchase
WATCH LIST
5
YM BioSciences (YM-T)

ON STOCKCHASE SINCE Sep 2006

Acquired by Gilead Feb/13

biotechnology/pharmaceutical

YM BioSciences

YM-T

1 watching          
Join the Discussion

YM BioSciences (YM-T) SAVE Dec, 31, 1969, 7:00 pm

0.00 0 (100%)

This company is not ACTIVE.

What the experts are saying about YM-T



  • All
  • Filtered
Signal Opinion Expert
TOP PICK
YM BioSciences(YM-T) 

March 26, 2008

Recently suffered when phase 3 testing failed. Has cash in the bank, has a long runway (cash on a burn rate). Have 2 products in phase 3, one of which is approved in India and China. Great opportunities. Way undervalued.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Recently suffered when phase 3 testing failed. Has cash in the bank, has a long runway (cash on a burn rate). Have 2 products in phase 3, one of which is approved in India and China. Great opportunities. Way undervalued.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Geoff Houlton

Senior Hea, Union Securities...

Price Price
$0.990
Owned Owned
No

BUY
YM BioSciences(YM-T) 

May 24, 2007

In spite of its setback, he still likes. Risks/reward at this point is not bad. Speculative.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
In spite of its setback, he still likes. Risks/reward at this point is not bad. Speculative.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hugh Cleland, C

Founding P, Northern Rivers Capi...

Price Price
$2.010
Owned Owned
Yes

DON'T BUY
YM BioSciences(YM-T) 

February 19, 2007

Was forced to cancel its cancer treatment trial. They do have some cash. Have another product in the pipeline, but it is in Cuba, which will keep US investors away.. It will take 6 months for the market to care again.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Was forced to cancel its cancer treatment trial. They do have some cash. Have another product in the pipeline, but it is in Cuba, which will keep US investors away.. It will take 6 months for the market to care again.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$1.860
Owned Owned
No

BUY
YM BioSciences(YM-T) 

January 24, 2007

Tesmilifene is the 1st compound they’ll have pivotal phase 3 results on and the stock should move up strongly. Behind that, Nimotuzumab is a great compound that has some interesting phase 2 trials. Great risk/reward.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Tesmilifene is the 1st compound they’ll have pivotal phase 3 results on and the stock should move up strongly. Behind that, Nimotuzumab is a great compound that has some interesting phase 2 trials. Great risk/reward.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hugh Cleland, C

Founding P, Northern Rivers Capi...

Price Price
$4.620
Owned Owned
Yes

BUY
YM BioSciences(YM-T) 

September 7, 2006

The only biotech stock that he owns. Accumulates on weakness. Had 2 trials on their cancer drug without getting approval, but this isn't a concern. Statistically difficult to get approval in 2 tries. Is expecting a successful end point. Have a fantastic pipeline of other drugs as well.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
The only biotech stock that he owns. Accumulates on weakness. Had 2 trials on their cancer drug without getting approval, but this isn't a concern. Statistically difficult to get approval in 2 tries. Is expecting a successful end point. Have a fantastic pipeline of other drugs as well.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hugh Cleland, C

Founding P, Northern Rivers Capi...

Price Price
$3.540
Owned Owned
Yes

Showing 1 to 5 of 5 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days